Document is current

Article History

Received: 31 March 2024

Accepted: 26 July 2024

First Online: 13 August 2024

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. This study was submitted to the ethics committee of the Medical Faculty of the University of Wuerzburg (DE/EKBY13) (Date February 19th, 2024, No. 20240122 03). The ethics committee considered the study a retrospective data analysis of pseudonymzied collected clinical routine data that did not require ethical approval by German law as long as publication of data is in anonymous form. All participants provided written informed consent to be included in the RHADAR database and allow their pseudonymized data to be analyzed.

: PPS received speaker’s fees and travel grants from Janssen-Cilag Galapagos, Eli Lilly, Boehringer/Ingelheim and AbbVie (less than $10,000 each) as well as research funding from Chugai (25000$). ME received payment for data analysis from RHADAR and consulting fees from Abbvie and RHADAR as well as speaker fees and honoraria for lectures from Sanofi, Swedish orphan Biovitrum and Abbvie. ME leadership or fiduciary role from Chugai. LMR declares that he has received travel and meeting support from Abbvie and Boehringer and speaking fees from Novartis. TW received honoraria for lectures from Abbvie, Amgen, BMS, Celgene, Fresenius Kabi, Galapagos, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, UCB. MF received speaker’s fees, travel grants or compensation for board memberships from AbbVie, Amgen, AstraZeneca, Novartis, Janssen, Hexal, Pfizer, Takeda, UCB and Eli Lilly. MS received speaker’s fees, travel grants, research funding, or compensation for consultancies or board memberships from AbbVie, Actelion, AstraZeneca, BMS, Boehringer/Ingelheim, Celgene, Chugai/Roche, Eli Lilly, Genzyme, Gilead, Hexal/Sandoz, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi Pasteur, Takeda (Shire), UCB (less than $ 10,000 each). MG received travel grants, compensation for advisory boards or speaker’s fees from AbbVie, Chugai, Eli Lilly, Hexal, Janssen, Novartis, Pfizer, Takeda AS declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. PBB declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. CvdD received travel grants from Galapagos and Abbvie. KK received speaker fees from Abbvie and UCB. GG received speaker fees and travel grants from Abbvie, Janssen, Galapagos, and Lilly. PW declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. SSM received speaker fees from Abbvie, Astra Zeneca, Boerhringer-Ingelheim, BMS, Galapagos, GSK, Lilly, MSD, Novartis, Pfizer, Sanofi, UCB. CK declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. WV declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. JH declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. MW declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. SK received grants from Abbvie, Novartis, and sparrow for phase 2/3 clinical trials and cosulting or speaker fees from Abbvie, Celgene, Chugai, Galapagos, Novartis, and Siemens Healthineers.